DEERFIELD, Ill. (AP) — Baxter International Inc. said Wednesday that it received European Commission approval for its swine flu vaccine. The specialty drug and medical device maker said preliminary clinical trial results show the Celvapan H1N1 vaccine is “well tolerated” by individuals 18 and older. “The observed systemic and local reactions are similar to those generally experienced after vaccination with licensed seasonal influenza vaccines,” the company said. Baxter said it will submit its immunogenicity results from the first adult vaccination to the European Medicines Agency within days. The company is trying to determine through its trials if a single dose of the swine flu vaccine is possible as well as if a lower dosage will be enough to prompt the necessary immune response.